Trial Profile
A retrospective study evaluating efficacy and safety of nivolumab in previously heavily pretreated patients with relapsed and refractory classical Hodgkin lymphoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology